Nexstem, a Bengaluru-based deep-tech startup has raised $3.5 million in its latest funding round co-led by InfoEdge, Zupee and Smile Group. The funding round also attracted prominent investors, such as Nikhil Kamath and Abhijeet Pai’s Gruhas.
The funds raised will be used to scale its latest product ecosystem and expand its intellectual property (IP) portfolio, leading to disruption in the neurotech sector. This funding will enable Nexstem to scale its operations to meet growing demand and deliver its highly customisable product line.
The funds will also support global expansion, particularly into American and European markets.
Siddhant Dangi, Co-founder, Nexstem, said, “With this funding, we are excited to advance the deployment of our BCI ecosystem, which we believe will redefine how technology can address real-world challenges across diverse sectors. Our focus is on harnessing complex biosignal data from the human body, which will help us create better products, and highly customised services and understand humans better than ever. By addressing these challenges, we are opening doors to applications once imagined in sci-fi, such as longevity and telepathy. Our approach as an early platform player enables us to help others realise impactful use cases in neurotechnology, carefully balancing innovation with practical applications.”
Vibhore Sharma, Tech Investments, InfoEdge, said, “We believe that BCI would emerge as an extremely transformative technology in the next decade or so and we are very excited to back the Nexstem team in their endeavour in this space. In an industry characterised by lengthy development cycles and substantial investment, Nexstem’s progress has been fast, frugal and exceptional.”
Abhijeet Pai, Co-founder of Gruhas, said, “Nexstem’s advancements in BCI are at the frontier of what’s possible in neurotechnology. Their unique approach to biosignal infrastructure and commitment to democratising BCI technology aligns with our vision for transformative tech that leaves a lasting impact.”
Founded in 2020 by Siddhant Dangi and Deepansh Goyal, Nexstem develops non-invasive brain-computer interface (BCI) solutions. BCI technology essentially enables direct communication between the human brain and external devices, a field once confined to science fiction but now rapidly advancing toward real-world applications.
Nexstem’s breakthrough product suite for BCI – Instinct leverages an artificial intelligence-powered onboard compute module that supports analysis for all kinds of biosignals from the human body. This platform provides a full-stack solution with hardware, SDKs, APIs, and algorithms, enabling robust, end-to-end BCI functionality.
From restoring lost motor functions to augmenting cognitive capabilities, BCI has the potential to redefine human-machine interactions in ways previously thought impossible, claimed the company.
Recognized by Microsoft for Startups, NASSCOM, and VIVA Tech Paris, Nexstem has garnered attention as a pioneering player in the neurotechnology field.
Despite the competitive nature of the industry, the BCI market is poised for significant growth, with Morgan Stanley’s latest report estimating the market at USD 400 billion in the US alone. Over the next three years, Nexstem aims to achieve significant milestones, including releasing the most awaited Nexstem Coin, EXG modules and tACS technology, adding to their existing product & IP portfolio, securing regional and compliance certifications and expanding into defence and consumer markets, supported by a robust distribution network.
